Reata Pharmaceuticals

BioNTX Champions Talent Retention in the Texas Life Sciences Industry

Retrieved on: 
Thursday, February 15, 2024

Through a series of career initiatives, the organization aims to support academic talent and professionals affected by recent layoffs in the pharmaceutical sector, providing opportunities for career advancement within the North Texas life science industry.

Key Points: 
  • Through a series of career initiatives, the organization aims to support academic talent and professionals affected by recent layoffs in the pharmaceutical sector, providing opportunities for career advancement within the North Texas life science industry.
  • "Our ‘Keeping Talent in Texas and ‘Talent Network Career Expo’ events reflect BioNTX's unwavering commitment to the professionals who contribute significantly to the North Texas biotech and healthcare innovation industry.
  • We are dedicated to creating opportunities for this wealth of talent to thrive in North Texas," said Kathleen M. Otto, CEO at BioNTX.
  • As BioNTX continues to lead the charge in supporting talent retention and industry growth, the organization invites all stakeholders to join in its mission to cultivate a dynamic and flourishing biotech community in North Texas.

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Retrieved on: 
Thursday, February 15, 2024

“We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni’s caliber to our Board of Directors,” said David Lamond, chairperson of Quince’s Board of Directors.

Key Points: 
  • “We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni’s caliber to our Board of Directors,” said David Lamond, chairperson of Quince’s Board of Directors.
  • Most recently, he served as Chief Research and Development Officer at Reata Pharmaceuticals, a commercial-stage company recently acquired by Biogen.
  • Previously, Dr. Patni also served as Chief Medical Officer at several successful public, small-cap, and commercial-stage biopharmaceutical companies – Global Blood Therapeutics, Portola Pharmaceuticals, and Adamas Pharmaceuticals.
  • Earlier in his career, Dr. Patni held roles of increasing responsibility at Pfizer, Roche, and Actelion.

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Retrieved on: 
Monday, February 5, 2024

“The accumulating talent bench at Lexeo has overseen some of the most transformative clinical development programs, drug approvals and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics.

Key Points: 
  • “The accumulating talent bench at Lexeo has overseen some of the most transformative clinical development programs, drug approvals and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics.
  • During her tenure, Dr. See Tai led the late-stage clinical development program of tafamidis for ATTR cardiomyopathy (ATTR-ACT), which achieved global regulatory approvals, and the Phase 3 LMNA dilated cardiomyopathy clinical program.
  • In addition to late-stage clinical development, Dr. See Tai was responsible for strategic clinical planning for early-stage development candidates such as those for other genetic cardiomyopathies and Duchenne Muscular Dystrophy.
  • Dr. Adler’s work has led to the development of a novel cardiovascular gene therapy candidate entering late-stage clinical development.

MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors

Retrieved on: 
Monday, February 5, 2024

CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors.

Key Points: 
  • CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors.
  • Dr. Ryder is an accomplished biopharmaceutical executive with over 35 years of global drug development experience and industry leadership.
  • “I am delighted to welcome Steve to our Board of Directors, and we look forward to his leadership as we progress our pipeline of novel therapies for people with rare endocrine disorders,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
  • “I am honored to join the MBX Board during this exciting period of growth for the Company,” said Dr. Ryder.

Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer

Retrieved on: 
Tuesday, January 23, 2024

CAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.
  • “We are thrilled to welcome Dr. Khan to the Alkeus executive team as we pursue our mission to innovate transformative therapies for degenerative eye diseases,” said Leonide Saad, Ph.D., President and CEO at Alkeus.
  • “An accomplished executive, Dr. Khan has a track record in bringing rare disease treatments to patients in need across multiple therapeutic areas.”
    Prior to joining Alkeus, Dr. Khan served as Chief Medical Officer at Reata Pharmaceuticals through its acquisition by Biogen, where she oversaw all clinical programs from early stage to commercialization.
  • My commitment to medical innovation and patient care aligns seamlessly with Alkeus' mission, and I look forward to driving forward this life-changing treatment."

Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock

Retrieved on: 
Monday, January 8, 2024

PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

Key Points: 
  • PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • YOU ARE ALSO NOTIFIED that Lead Plaintiff in the Action has reached a proposed settlement of the Action for $45,000,000 in cash (the "Settlement"), that, if approved, will resolve all claims in the Action.
  • If you are a member of the Settlement Class, your rights will be affected by the pending Action and the Settlement, and you may be entitled to share in the Settlement Fund.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement, should be directed to Lead Counsel or the Claims Administrator.

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Retrieved on: 
Monday, December 11, 2023

NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates.

Key Points: 
  • Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product Development and Medical Officer of BioXcel Therapeutics.
  • Additionally, Rajiv Patni, M.D., has been appointed to the newly created position of Strategic Clinical Advisor to the BioXcel Therapeutics Chief Executive Officer and Board of Directors.
  • Prior to joining BioXcel Therapeutics, Dr. O’Neill held senior leadership roles at several leading global pharmaceutical companies, including Sanofi, Genentech, and GlaxoSmithKline.
  • “I look forward to working with the BioXcel leadership team in continuing to address the unmet medical needs of patients and caregivers and advance the Company’s product-development goals.”

Lazard LTD Reports Third-Quarter and Nine-Month 2023 Results

Retrieved on: 
Thursday, October 26, 2023

For a list of publicly announced Financial Advisory transactions on which Lazard advised in the third quarter of 2023, or continued to advise or completed since September 30, 2023, please visit our website at www.lazard.com/financial-advisory/transactions/ .

Key Points: 
  • For a list of publicly announced Financial Advisory transactions on which Lazard advised in the third quarter of 2023, or continued to advise or completed since September 30, 2023, please visit our website at www.lazard.com/financial-advisory/transactions/ .
  • For the third quarter of 2023, Asset Management operating revenue was $262 million, flat compared to the third quarter of 2022.
  • AUM as of September 30, 2023, was $228 billion, 5% lower than June 30, 2023, and 15% higher than September 30, 2022.
  • ET on October 26, 2023, to discuss the company’s financial results for the third quarter and first nine months of 2023.

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

Retrieved on: 
Monday, October 16, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer.
  • “Mishima brings a dynamic set of drug development experiences including the design and execution of global regulatory strategies in support of preclinical to commercial-stage programs,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer at Pliant.
  • Ms. Gerhart previously held the role of Chief Regulatory Officer and Head of Quality at Taysha Gene Therapies where she established and grew the regulatory and quality organizations and was responsible for all US and Ex-US regulatory interactions.
  • Prior to this, Ms. Gerhart was Head of Regulatory at Genzyme and held regulatory positions of increasing seniority at AbbVie, Reata Pharmaceuticals, Pfizer/ Wyeth, AstraZeneca, and Wyeth.

Healthcare M&A Volume Falls in Q3:23, According to Acquisition Data from LevinPro HC

Retrieved on: 
Thursday, October 12, 2023

NEW CANAAN, Conn., Oct. 12, 2023 /PRNewswire-PRWeb/ -- Health care merger and acquisition activity declined in the third quarter of 2023, dropping to 497 deals, according to new acquisition data from LevinPro HC. Activity in the third quarter was 16% lower than in the second quarter, when 598 transactions were announced. Compared with the third quarter of 2022, activity fell 19% in the third quarter of 2023.

Key Points: 
  • Health care merger and acquisition activity declined in the third quarter of 2023, dropping to 497 deals, according to new acquisition data from LevinPro HC.
  • NEW CANAAN, Conn., Oct. 12, 2023 /PRNewswire-PRWeb/ -- Health care merger and acquisition activity declined in the third quarter of 2023, dropping to 497 deals, according to new acquisition data from LevinPro HC.
  • "It seems like the macro headwinds have finally caught up to the healthcare M&A market," said Dylan Sammut, Editor of Health Care at Irving Levin Associates, which publishes M&A data on its LevinPro HC platform.
  • The company publishes research reports and newsletters and maintains databases on the healthcare and senior housing M&A markets.